Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysis.

Autor: Clapham RE; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, UK. Electronic address: rachel.clapham@kcl.ac.uk., Speed V; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK., Byrne R; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Roberts LN; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Czuprynska J; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Gee E; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Duffy S; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Patel R; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Patel RK; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Arya R; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK., Patel JP; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, UK; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, UK.

Publikováno v: Thrombosis research [Thromb Res] 2024 Oct; Vol. 242, pp. 109118. Date of Electronic Publication: 2024 Aug 14.

Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.

Autor: Clapham RE; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Speed V; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.; Institute of Pharmaceutical Sciences, King's College London, London, UK., Czuprynska J; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Gazes A; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Guppy S; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Patel RK; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Rea C; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Vadher B; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Arya R; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK., Roberts LN; King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. e3-e6. Date of Electronic Publication: 2021 Aug 05.